Clofibric acid: a potential therapeutic agent in AML and MDS

Differentiation therapy using retinoic acids (RAs) or 1 alpha 25-dihydroxyv itamin D-3 (D-3) is an attractive alternative to chemotherapy in acute myel oid leukaemia (AML) and myelodysplastic syndromes (MDS), However, with the exception of RA therapy for acute promyelocytic leukaemia (APL), RAs and D- 3 are not potent enough at doses that can be tolerated by patients. We demo nstrate that clofibric acid (CA) enhances the response of HL60 cells to all -trans RA and D-3 Our Endings and those of others in the field lead us to s uggest that combination therapy using all-trans RA and CA should be conside red as potential therapy for AML and MDS.